Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Protease Inhibitors


Glossary of Terms for Supplement
Glossary of Terms for Supplement
Carcinogenic = producing or tending to produce cancer
  • Some agents, such as certain chemicals or forms of radiation, are both mutagenic and clastogenic.
  • Genetic mutations and/or chromosomal damage can contribute to cancer formation.
Clastogenic = causing disruption of or breakages in chromosomes
Genotoxic = damaging to genetic material such as DNA and chromosomes
Mutagenic = inducing or capable of inducing genetic mutation
Teratogenic = interfering with fetal development and resulting in birth defects

For information regarding the protease inhibitor (PI) class of drugs and potential metabolic complications during pregnancy and pregnancy outcome, see Combination Antiretroviral Drug Regimens and Pregnancy Outcome.

Atazanavir (Reyataz, ATV)
Darunavir (Prezista, DRV)
Fosamprenavir (Lexiva, FPV)
Indinavir (Crixivan, IDV)
Lopinavir/Ritonavir (Kaletra, LPV/r)
Nelfinavir (Viracept, NFV)
Saquinavir (Invirase [Hard Gel Capsule], SQV)
Tipranavir (Aptivis, TPV)

Download Guidelines